Terrestrial Bio Raises $50M Series C to Scale Needle-Free Drug Delivery Platform

The future of medicine might not look like a breakthrough, it might look like something you barely notice, and Terrestrial Bio is betting that subtlety scales better than spectacle. Born as Vaxess Technologies out of Cambridge back in 2011, the company spent years doing the unglamorous work across silk science, stabilization, and delivery mechanics, building the kind of deep tech that doesn’t trend but quietly compounds, as Michael A. Schrader, Kathryn Kosuda, Livio Valenti, and Patrick Ho anchored the company in a simple but uncomfortable question: why does breakthrough medicine still show up with a needle attached?

Fast forward to now, and Terrestrial Bio just pulled in $50M in Series C funding led by RA Capital Management, with Engine Ventures, Global Health Investment Corporation, and SiteGround stepping in, which signals more than capital, it reflects conviction from investors who understand how unforgiving biology can be when you try to improve both experience and efficacy at the same time.

Rachel Sha, CEO, is steering with the kind of precision earned inside complex systems, while Kathryn Kosuda, CSO and co-founder continues to operate where the real edge lives, deep in the science, and that duality between vision and execution is exactly where companies either separate or stall.

The product sounds simple until you sit with it for a second, a microarray patch delivering therapies like GLP-1 through dissolvable microstructures in the skin, removing the syringe, stripping away the ritual, and compressing the experience down to apply, wait, and move on, which quietly turns adherence from a behavioral hurdle into something far more automatic.

Patients in human factors work didn’t just accept it, they preferred it, and that preference isn’t cosmetic, it’s a shift in behavior, the kind investors recognize early because it compounds across populations, outcomes, and ultimately markets.

The $50M is being directed into a Boston-based manufacturing buildout at Allston Labworks, pushing toward scaled production and late-stage development for GLP-1 programs, which is where the story moves from promising science to repeatable infrastructure.

For founders watching closely, the lesson sits beneath the headline, Terrestrial Bio didn’t rush to be seen, they built layer by layer through non-dilutive funding, biopharma partnerships, and platform validation, so when this round landed, it read less like a milestone and more like a confirmation.

The rhythm here is deliberate, slow early, then suddenly obvious, and when the delivery mechanism evolves, the market doesn’t just grow, it opens in ways that were previously gated by friction. Because the real unlock isn’t always the drug, it’s how seamlessly it fits into the life of the person who needs it.